Antipsychotics (APDs) represent a core treatment for severe mental disorders (SMEs).
Providing symptomatic relief, APDs do not exert therapeutic effects on another clinically …

Schizophrenia is a neuropsychiatric disorder that chronically affects 21 million people
worldwide. Second-generation antipsychotics (SGAs) are the cornerstone in the …

Aims/hypothesis Second-generation antipsychotic (SGA) drugs have been associated with
the development of type 2 diabetes and the metabolic syndrome in patients with …

Objective Leptin and adiponectin are adipokines which have opposing roles in the
development of insulin resistance and metabolic syndrome (MetS). Leptin/adiponectin ratio …

Aim Widely used second‐generation antipsychotics are associated with adverse metabolic
effects, contributing to increased cardiovascular mortality. To develop strategies to prevent …

Cardiometabolic diseases are the main contributor of reduced life expectancy in patients
with schizophrenia. It is now widely accepted that antipsychotic treatment plays an important …

Background: Olanzapine, regarded as one of the most efficacious antipsychotic medications
for the treatment of schizophrenia, is associated with a high risk of weight gain and …

Olanzapine is a widely used atypical antipsychotic medication for treatment of schizophrenia
and is often associated with serious metabolic abnormalities including weight gain and …

This work aims at designing an innovative poly (vinyl alcohol)(PVA) adhesive film containing
nanostructured lipid carriers (NLC) loaded with olanzapine (OL) and simvastatin (SV), for the …

Objective Schizophrenia is associated with an increased prevalence of the metabolic
syndrome. Patients receiving antipsychotic medications, including olanzapine, are at further …